Literature DB >> 7429112

Chronic asymptomatic HBSAg carriers: histologic abnormalities and diagnostic and prognostic value of serologic markers of the HBV.

R De Franchis, A D'Arminio, M Vecchi, G Ronchi, E Del Ninno, A Parravicini, P Ferroni, A R Zanetti.   

Abstract

Liver histology, the serum "e" antigen system, and DNA-polymerase activity were studied in 68 chronic asymptomatic HBSAg carriers with normal liver chemistries in order to assess the frequency of chronic hepatitis and the diagnostic and prognostic usefulness of serum HBV markers in these subjects. Liver histology was normal in 3 cases, showed nonspecific changes in 46, chronic-persistent hepatitis in 16, and moderate chronic active hepatitis in 3. The "e" antigen and DNA-polymerase activity were positive in 2 and 5 cases, respectively, and were associated with either minimal inflammatory changes or chronic-persistent hepatitis. The "e" antibody was found in 28, evenly distributed among the varios histologic categories; 2 out of 3 patients with chronic active hepatitis carried the "e" antibody. Sixty-four patients have been followed prospectively for 12-30 mo with serial liver tests. During follow-up, 1 patient, with minimal inflammatory changes on liver biopsy and negative for "e" antigen, antibody or DNA-polymerase activity, developed consistently abnormal transaminases, and showed progression to chronic active hepatitis on repeat biopsy. In another patient with chronic-persistent hepatitis, "e" antigen and DNA-polymerase activity reverted to entirely normal serologic status. In our large series, the frequency of chronic hepatitis among HBSAg carriers with normal liver chemistries was somewhat higher than previously reported. In these subjects, the "e" antigen status did not correlate closely with liver histology and did not seem to provide reliable short-term prognostic information.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7429112

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  9 in total

Review 1.  Natural history of the HBsAg carrier.

Authors:  M G Anderson; I M Murray-Lyon
Journal:  Gut       Date:  1985-08       Impact factor: 23.059

2.  Hepatitis viruses in southern Taiwan--mass survey of 2985 inhabitants.

Authors:  S S Chiou; H Obata; T Takasaki; Y Fukushima; Y Motoike; H Okuda; S Tanaka; T Kurihara; M Tomimatsu; S Kobayashi
Journal:  Gastroenterol Jpn       Date:  1984-08

3.  Animal model of human disease. Chimpanzee carriers of hepatitis B virus. Chimpanzee hepatitis B carriers.

Authors:  S N Thung; M A Gerber; R H Purcell; W T London; K B Mihalik; H Popper
Journal:  Am J Pathol       Date:  1981-12       Impact factor: 4.307

4.  Should chronic HBV infected patients with normal ALT treated: debate.

Authors:  Shiv Kumar Sarin; Manoj Kumar
Journal:  Hepatol Int       Date:  2008-03-04       Impact factor: 6.047

Review 5.  Hepatitis B in pregnancy.

Authors:  J A Arevalo
Journal:  West J Med       Date:  1989-06

6.  Permanent HBsAg clearance in chronic hepatitis B viral infection following acute delta superinfection.

Authors:  K P Chin; S Govindarajan; A G Redeker
Journal:  Dig Dis Sci       Date:  1988-07       Impact factor: 3.199

7.  Hepatitis B e-antigen titres for evaluating infectivity during hepatitis B virus infection.

Authors:  E G Lindenschmidt; C F Granato; C Salefsky; R Laufs; H Henning
Journal:  Klin Wochenschr       Date:  1984-03-01

8.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047

Review 9.  DNA-guided hepatitis B treatment, viral load is essential, but not sufficient.

Authors:  Rafael Bárcena Marugán; Silvia García Garzón
Journal:  World J Gastroenterol       Date:  2009-01-28       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.